BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25215925)

  • 1. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
    Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
    J Med Econ; 2014 Dec; 17(12):862-71. PubMed ID: 25215925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.
    LaMori J; Tandon N; Laliberté F; Germain G; Pilon D; Lefebvre P; Prabhakar A
    J Med Econ; 2016; 19(4):364-73. PubMed ID: 26624985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
    Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
    Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.
    Manos MM; Darbinian J; Rubin J; Ray GT; Shvachko V; Denis B; Velez F; Quesenberry C
    J Manag Care Pharm; 2013; 19(6):438-47. PubMed ID: 23806057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.
    Le TK; Macaulay D; Kalsekar A; Yuan Y; Sorg RA; Wei J; Wu EQ
    Clin Ther; 2015 Aug; 37(8):1713-25.e3. PubMed ID: 26111918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
    McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
    J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia.
    Poordad F; Theodore D; Sullivan J; Grotzinger K
    J Med Econ; 2011; 14(2):194-206. PubMed ID: 21348807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resource use and cost of hepatitis C-related care.
    Nevens F; Colle I; Michielsen P; Robaeys G; Moreno C; Caekelbergh K; Lamotte M; Wyffels V
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1191-8. PubMed ID: 22836284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims' Data.
    Ki M; Choi HY; Kim KA; Jang ES; Jeong SH
    Gut Liver; 2017 Nov; 11(6):835-842. PubMed ID: 28798283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
    J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
    Roebuck MC; Liberman JN
    Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study.
    McElroy HJ; Roberts SK; Thompson AJ; Angus PW; McKenna SJ; Warren E; Musgrave S
    J Med Econ; 2017 Jan; 20(1):72-81. PubMed ID: 27552282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
    Wu EQ; Forsythe A; Guérin A; Yu AP; Latremouille-Viau D; Tsaneva M
    Am J Ther; 2012 Nov; 19(6):e157-66. PubMed ID: 21317625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy.
    Han SH; Jing W; Mena E; Li M; Pinsky B; Tang H; Hebden T; Juday T
    J Med Econ; 2012; 15(6):1159-66. PubMed ID: 22780707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
    Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
    J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
    Stahmeyer JT; Rossol S; Bert F; Antoni C; Demir M; Hinrichsen H; Hüppe D; Teuber G; Wiebner B; Wedemeyer H; Krauth C
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1278-85. PubMed ID: 25144493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
    Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
    Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.